2005 Annual report - Virbac
2005 Annual report - Virbac
2005 Annual report - Virbac
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>2005</strong> <strong>Annual</strong> Report<br />
16<br />
Innovation<br />
More “customer focused” innovation<br />
Since its founding <strong>Virbac</strong> has had a customer focused innovation process that<br />
tightly links Research, Development and Licensing (RDL). In order to improve the<br />
success of its innovation process against a background of increased regulatory<br />
pressure, <strong>Virbac</strong> has for the past number of years been optimising its organisation<br />
and working methods so as to strengthen the selection process for new projects.<br />
In <strong>2005</strong>, new products introduced within the past 3 years thus generated 15% of<br />
sales.<br />
Responsiveness and novelty<br />
of key differentiation drivers<br />
Paying close attention to market requirements, responsiveness and novelty of the<br />
approach are key factors to the success of <strong>Virbac</strong> innovations. In September <strong>2005</strong>,<br />
the Group was able, within record time, to take advantage of the market<br />
opportunity provided by the expiry, in France, of the ivermectin patent. <strong>Virbac</strong><br />
thus simultaneously launched no less than six ivermectin-based products<br />
marketed in different guises (pour-on, oral paste, injectable) for cattle, pigs, sheep<br />
and horses thereby creating the broadest and most complete new range on the<br />
market.
Change language